These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37671166)

  • 21. Predictors of the Onset of Type 1 Diabetes Obtained from Real-World Data Analysis in Cancer Patients Treated with Immune Checkpoint Inhibitors.
    Takada S; Hirokazu H; Yamagishi K; Hideki S; Masayuki E
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1697-1699. PubMed ID: 32592366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma.
    Akturk HK; Couts KL; Baschal EE; Karakus KE; Van Gulick RJ; Turner JA; Pyle L; Robinson WA; Michels AW
    JAMA Netw Open; 2022 Dec; 5(12):e2246400. PubMed ID: 36512357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus.
    Liao D; Liu C; Chen S; Liu F; Li W; Shangguan D; Shi Y
    Int Immunopharmacol; 2023 Sep; 122():110414. PubMed ID: 37390646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
    Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
    BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and HLA genotype analysis of immune checkpoint inhibitor-associated diabetes mellitus: a single-center case series from China.
    Liu YC; Liu H; Zhao SL; Chen K; Jin P
    Front Immunol; 2023; 14():1164120. PubMed ID: 37359544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type 1 diabetes mellitus affected by potential toxicity from long-term use of nivolumab.
    Motomura Y; Urai S; Hirota Y; Takegawa N; Bando H; Yamamoto M; Fukuoka H; Tsuda M; Ogawa W
    Diabetol Int; 2024 Jan; 15(1):130-134. PubMed ID: 38264226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct changes to pancreatic volume rather than pancreatic autoantibody positivity: insights into immune checkpoint inhibitors induced diabetes mellitus.
    Wei HH; Lai YC; Lin G; Lin CW; Chang YC; Chang JW; Liou MJ; Chen IW
    Diabetol Metab Syndr; 2024 Jan; 16(1):26. PubMed ID: 38254155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
    Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
    Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab.
    Mae S; Kuriyama A; Tachibana H
    J Emerg Med; 2021 Mar; 60(3):342-344. PubMed ID: 33097350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature.
    Ning P; Liu S; Cao H
    J Med Case Rep; 2024 Jan; 18(1):51. PubMed ID: 38247005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health-related quality of life in survivors of advanced melanoma treated with anti-PD1-based immune checkpoint inhibitors.
    Looman EL; Cheng PF; Lai-Kwon J; Morgan L; Wakkee M; Dummer R; Dimitriou F
    Cancer Med; 2023 Jun; 12(11):12861-12873. PubMed ID: 37119050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center.
    Jeun R; Iyer PC; Best C; Lavis V; Varghese JM; Yedururi S; Brady V; Glitza Oliva IC; Dadu R; Milton DR; Brock K; Thosani S
    Immunotherapy; 2023 Apr; 15(6):417-428. PubMed ID: 37013834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus.
    Muniz TP; Araujo DV; Savage KJ; Cheng T; Saha M; Song X; Gill S; Monzon JG; Grenier D; Genta S; Allen MJ; Arteaga DP; Saibil SD; Butler MO; Spreafico A; Hogg D
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
    Iravani A; Osman MM; Weppler AM; Wallace R; Galligan A; Lasocki A; Hunter MO; Akhurst T; Hofman MS; Lau PKH; Kee D; Au-Yeung G; Sandhu S; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2776-2786. PubMed ID: 32338306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes.
    Chen X; Affinati AH; Lee Y; Turcu AF; Henry NL; Schiopu E; Qin A; Othus M; Clauw D; Ramnath N; Zhao L
    Diabetes Care; 2022 May; 45(5):1170-1176. PubMed ID: 35238899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
    Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
    Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function.
    Jessel S; Weiss SA; Austin M; Mahajan A; Etts K; Zhang L; Aizenbud L; Perdigoto AL; Hurwitz M; Sznol M; Herold KC; Kluger HM
    Front Oncol; 2022; 12():836859. PubMed ID: 35350573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.